Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
  2. A company based in Sunnyvale sought FDA approval for therapies and held a conference in New York City.

LENZ Therapeutics is engaged with the FDA regarding LNZ100.

5 reports, 2 independent Updated Jul 6
Gone quiet Reached 2 outlets in its first 24 hours
Reports
5
Developments
3
Repetition
60%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

LENZ Therapeutics is engaged with the FDA regarding LNZ100.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Laboratoires Théa received an exclusive license for the drug LNZ100 from LENZ Therapeutics.Sub-event
  2. LENZ Therapeutics received FDA approval and presented its product VIZZ at a conference in NYC.1 source
  3. Ongoing discussions between LENZ Therapeutics and the FDA regarding the LNZ100 product.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireLENZ Therapeutics to Present at Upcoming Investor and Medical Conferences SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceuti
  • Simply Wall St.Will FDA Approval of Vizz Eye Drops Change LENZ Therapeutics' (LENZ) Narrative? LENZ Therapeutics recently received FDA approval for its Vizz eye drops to treat presbyopia in adults, offering a new n
  • GlobeNewswireLENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a
  • GlobeNewswireLENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date
1 more outlet ran the same wire story